1 | despite | 18,140 |
2 | amidst | 15 |
3 | athough | 4 |
4 | configuring | 4 |
5 | background- | 3 |
6 | formycin | 3 |
7 | 3-methylcrotonyl-coenzyme | 2 |
8 | aim-induced | 2 |
9 | nyt-treatment | 2 |
10 | prebending | 2 |
11 | presupposing | 2 |
12 | pretwisting | 2 |
13 | rates.in | 2 |
14 | twelve-bed | 2 |
15 | virus.a | 2 |
16 | 'record | 1 |
17 | 1.when | 1 |
18 | 15-epi-lipoxin | 1 |
19 | 2015.-with | 1 |
20 | 24306696 | 1 |
21 | 3.in | 1 |
22 | 4.in | 1 |
23 | 6500-element | 1 |
24 | 7-o-methylvariecolortide | 1 |
25 | 9,785 | 1 |
26 | accelerometry-assessed | 1 |
27 | acovegine | 1 |
28 | afterigniting | 1 |
29 | alltogether | 1 |
30 | alteramide | 1 |
31 | althought | 1 |
32 | amassing | 1 |
33 | andriolo | 1 |
34 | anthocyanone | 1 |
35 | asess | 1 |
36 | avsc | 1 |
37 | background.-despite | 1 |
38 | balanoposthitisis | 1 |
39 | bothe | 1 |
40 | botulinumtoxin | 1 |
41 | carvalheira | 1 |
42 | conceming | 1 |
43 | cs6-immunoglobulin | 1 |
44 | cyclacel | 1 |
45 | cyclolinopeptide | 1 |
46 | delecting | 1 |
47 | dimitrij | 1 |
48 | doxorubicinis | 1 |
49 | electrocardiographycally | 1 |
50 | galones | 1 |
51 | giardiasis- | 1 |
52 | hingelike | 1 |
53 | hydroximetilglutaril-coenzima | 1 |
54 | intense/very | 1 |
55 | irct201107317161n1 | 1 |
56 | irct2012121711790n1 | 1 |
57 | irct201303135393n2 | 1 |
58 | isoneochamaejasmin | 1 |
59 | isrctn55318418 | 1 |
60 | ivacaftorcarries | 1 |
61 | last-decade | 1 |
62 | left-without | 1 |
63 | liraglutide-associated | 1 |
64 | mb-80 | 1 |
65 | mcf-10f | 1 |
66 | melicolones | 1 |
67 | metfromin | 1 |
68 | methods- | 1 |
69 | mildronat | 1 |
70 | misaligning | 1 |
71 | modulation.in | 1 |
72 | n'-disuccinimidylcarbonate | 1 |
73 | nanofluids- | 1 |
74 | nimally | 1 |
75 | organisation/responsibility | 1 |
76 | ougi-keishi-gomotsu-to | 1 |
77 | participants-anyone | 1 |
78 | phobically | 1 |
79 | post-meiotically | 1 |
80 | post-optimization | 1 |
81 | practice-induced | 1 |
82 | provider-ordered | 1 |
83 | pvi-based | 1 |
84 | qubeis | 1 |
85 | re-developing | 1 |
86 | recollecting | 1 |
87 | redeveloping | 1 |
88 | reinserting | 1 |
89 | replot | 1 |
90 | ryecyanatines | 1 |
91 | self-accessing | 1 |
92 | serfling-type | 1 |
93 | similiarly | 1 |
94 | siplizumab-related | 1 |
95 | srctn39391017 | 1 |
96 | stenophyllum | 1 |
97 | strated | 1 |
98 | strategies-has | 1 |
99 | tape-record | 1 |
100 | theres | 1 |
101 | tocilizumab-associated | 1 |
102 | toxicity/hypersensitivity | 1 |
103 | undulatumoside | 1 |
104 | unparallel | 1 |
105 | vernolide | 1 |
106 | wetested | 1 |
107 | ιn | 1 |
1 | 'record | 1 |
2 | 1.when | 1 |
3 | 15-epi-lipoxin | 1 |
4 | 2015.-with | 1 |
5 | 24306696 | 1 |
6 | 3-methylcrotonyl-coenzyme | 2 |
7 | 3.in | 1 |
8 | 4.in | 1 |
9 | 6500-element | 1 |
10 | 7-o-methylvariecolortide | 1 |
11 | 9,785 | 1 |
12 | accelerometry-assessed | 1 |
13 | acovegine | 1 |
14 | afterigniting | 1 |
15 | aim-induced | 2 |
16 | alltogether | 1 |
17 | alteramide | 1 |
18 | althought | 1 |
19 | amassing | 1 |
20 | amidst | 15 |
21 | andriolo | 1 |
22 | anthocyanone | 1 |
23 | asess | 1 |
24 | athough | 4 |
25 | avsc | 1 |
26 | background- | 3 |
27 | background.-despite | 1 |
28 | balanoposthitisis | 1 |
29 | bothe | 1 |
30 | botulinumtoxin | 1 |
31 | carvalheira | 1 |
32 | conceming | 1 |
33 | configuring | 4 |
34 | cs6-immunoglobulin | 1 |
35 | cyclacel | 1 |
36 | cyclolinopeptide | 1 |
37 | delecting | 1 |
38 | despite | 18,140 |
39 | dimitrij | 1 |
40 | doxorubicinis | 1 |
41 | electrocardiographycally | 1 |
42 | formycin | 3 |
43 | galones | 1 |
44 | giardiasis- | 1 |
45 | hingelike | 1 |
46 | hydroximetilglutaril-coenzima | 1 |
47 | intense/very | 1 |
48 | irct201107317161n1 | 1 |
49 | irct2012121711790n1 | 1 |
50 | irct201303135393n2 | 1 |
51 | isoneochamaejasmin | 1 |
52 | isrctn55318418 | 1 |
53 | ivacaftorcarries | 1 |
54 | last-decade | 1 |
55 | left-without | 1 |
56 | liraglutide-associated | 1 |
57 | mb-80 | 1 |
58 | mcf-10f | 1 |
59 | melicolones | 1 |
60 | metfromin | 1 |
61 | methods- | 1 |
62 | mildronat | 1 |
63 | misaligning | 1 |
64 | modulation.in | 1 |
65 | n'-disuccinimidylcarbonate | 1 |
66 | nanofluids- | 1 |
67 | nimally | 1 |
68 | nyt-treatment | 2 |
69 | organisation/responsibility | 1 |
70 | ougi-keishi-gomotsu-to | 1 |
71 | participants-anyone | 1 |
72 | phobically | 1 |
73 | post-meiotically | 1 |
74 | post-optimization | 1 |
75 | practice-induced | 1 |
76 | prebending | 2 |
77 | presupposing | 2 |
78 | pretwisting | 2 |
79 | provider-ordered | 1 |
80 | pvi-based | 1 |
81 | qubeis | 1 |
82 | rates.in | 2 |
83 | re-developing | 1 |
84 | recollecting | 1 |
85 | redeveloping | 1 |
86 | reinserting | 1 |
87 | replot | 1 |
88 | ryecyanatines | 1 |
89 | self-accessing | 1 |
90 | serfling-type | 1 |
91 | similiarly | 1 |
92 | siplizumab-related | 1 |
93 | srctn39391017 | 1 |
94 | stenophyllum | 1 |
95 | strated | 1 |
96 | strategies-has | 1 |
97 | tape-record | 1 |
98 | theres | 1 |
99 | tocilizumab-associated | 1 |
100 | toxicity/hypersensitivity | 1 |
101 | twelve-bed | 2 |
102 | undulatumoside | 1 |
103 | unparallel | 1 |
104 | vernolide | 1 |
105 | virus.a | 2 |
106 | wetested | 1 |
107 | ιn | 1 |
1 | background- | 3 |
2 | nanofluids- | 1 |
3 | methods- | 1 |
4 | giardiasis- | 1 |
5 | mb-80 | 1 |
6 | irct2012121711790n1 | 1 |
7 | irct201107317161n1 | 1 |
8 | irct201303135393n2 | 1 |
9 | 9,785 | 1 |
10 | 24306696 | 1 |
11 | srctn39391017 | 1 |
12 | isrctn55318418 | 1 |
13 | virus.a | 2 |
14 | hydroximetilglutaril-coenzima | 1 |
15 | carvalheira | 1 |
16 | avsc | 1 |
17 | twelve-bed | 2 |
18 | practice-induced | 1 |
19 | aim-induced | 2 |
20 | provider-ordered | 1 |
21 | pvi-based | 1 |
22 | accelerometry-assessed | 1 |
23 | tocilizumab-associated | 1 |
24 | liraglutide-associated | 1 |
25 | siplizumab-related | 1 |
26 | strated | 1 |
27 | wetested | 1 |
28 | 'record | 1 |
29 | tape-record | 1 |
30 | last-decade | 1 |
31 | vernolide | 1 |
32 | alteramide | 1 |
33 | undulatumoside | 1 |
34 | cyclolinopeptide | 1 |
35 | 7-o-methylvariecolortide | 1 |
36 | bothe | 1 |
37 | hingelike | 1 |
38 | 3-methylcrotonyl-coenzyme | 2 |
39 | acovegine | 1 |
40 | anthocyanone | 1 |
41 | participants-anyone | 1 |
42 | serfling-type | 1 |
43 | n'-disuccinimidylcarbonate | 1 |
44 | despite | 18,140 |
45 | background.-despite | 1 |
46 | mcf-10f | 1 |
47 | prebending | 2 |
48 | conceming | 1 |
49 | misaligning | 1 |
50 | re-developing | 1 |
51 | redeveloping | 1 |
52 | configuring | 4 |
53 | presupposing | 2 |
54 | amassing | 1 |
55 | self-accessing | 1 |
56 | delecting | 1 |
57 | recollecting | 1 |
58 | afterigniting | 1 |
59 | reinserting | 1 |
60 | pretwisting | 2 |
61 | athough | 4 |
62 | 2015.-with | 1 |
63 | dimitrij | 1 |
64 | cyclacel | 1 |
65 | unparallel | 1 |
66 | stenophyllum | 1 |
67 | 1.when | 1 |
68 | 3.in | 1 |
69 | 4.in | 1 |
70 | modulation.in | 1 |
71 | rates.in | 2 |
72 | formycin | 3 |
73 | cs6-immunoglobulin | 1 |
74 | metfromin | 1 |
75 | isoneochamaejasmin | 1 |
76 | 15-epi-lipoxin | 1 |
77 | botulinumtoxin | 1 |
78 | post-optimization | 1 |
79 | ιn | 1 |
80 | andriolo | 1 |
81 | ougi-keishi-gomotsu-to | 1 |
82 | alltogether | 1 |
83 | strategies-has | 1 |
84 | ivacaftorcarries | 1 |
85 | ryecyanatines | 1 |
86 | galones | 1 |
87 | melicolones | 1 |
88 | theres | 1 |
89 | qubeis | 1 |
90 | doxorubicinis | 1 |
91 | balanoposthitisis | 1 |
92 | asess | 1 |
93 | mildronat | 1 |
94 | althought | 1 |
95 | 6500-element | 1 |
96 | nyt-treatment | 2 |
97 | replot | 1 |
98 | amidst | 15 |
99 | left-without | 1 |
100 | phobically | 1 |
101 | post-meiotically | 1 |
102 | electrocardiographycally | 1 |
103 | nimally | 1 |
104 | similiarly | 1 |
105 | intense/very | 1 |
106 | organisation/responsibility | 1 |
107 | toxicity/hypersensitivity | 1 |